Prognostic factors and survival in metastatic breast cancer: A single institution experience

BackgroundThe current retrospective study aims to identify some determinants of survival in metastatic breast cancer.MethodsThe study concerned 332 patients with synchronous (SM) or metachronous (MM) metastatic breast cancer treated between January 2000 and December 2007. Statistical comparison between subgroups of patients concerning survival was carried out employing log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal status, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months vs. >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic disease (PS) (0–1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1), nature of the metastatic site (visceral vs. non visceral), first line therapy, surgery of the primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates.ResultsOverall survival at 5 years was 12%. Positive prognostic factors in univariate analysis were: age[[ce:hsp sp="0.25"/]]≤[[ce:hsp sp="0.25"/]]70 years, hormono-dependence of the tumor, good PS (PS 0–1), less than two metastatic sites, no visceral metastases, DFI[[ce:hsp sp="0.25"/]]≥[[ce:hsp sp="0.25"/]]24 months, SPT or LRRT. In multivariate analysis, favorable independent prognostic factors included: good PS (PS 0–1), absence of visceral metastases (liver, lung, brain) and age[[ce:hsp sp="0.25"/]]≤[[ce:hsp sp="0.25"/]]70 years.ConclusionMany of the prognostic factors in metastatic breast cancer found in our study are known in the literature but some of them, like the application of locoregional treatment (radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated in randomized clinical trials